ALB and renal cell adenocarcinoma: NLR/Alb, as a combined immune status and nutritional index, was first reported by Zhao et al. [18] to minimize the potential bias related to the nutritional and immune statuses of patients with cancer and has been a novel and strong prognostic factor for several cancers, including esophageal squamous cell carcinoma (ESCC) [18,19] and renal cell cancer (RCC) [20].